Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 19;21(20):7743.
doi: 10.3390/ijms21207743.

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Chang-Myung Oh  1 , Hong Jae Chon  2 , Chan Kim  2
Affiliations
Review

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Chang-Myung Oh et al. Int J Mol Sci. .

Abstract

Oncolytic virus (OV) is a new therapeutic strategy for cancer treatment. OVs can selectively infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Moreover, they can remodel the tumor microenvironment toward a T cell-inflamed phenotype by stimulating widespread host immune responses against the tumor. Recent evidence suggests several possible applications of OVs against cancer, especially in combination with immune checkpoint inhibitors. In this review, we describe the molecular mechanisms of oncolytic virotherapy and OV-induced immune responses, provide a brief summary of recent preclinical and clinical updates on this rapidly evolving field, and discuss a combinational strategy that is able to overcome the limitations of OV-based monotherapy.

Keywords: combination immunotherapy; immune checkpoint inhibitor; oncolytic virus; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of oncolytic virus (OV) anti-tumor effects.
See this image and copyright information in PMC

References

    1. Felix J., Savvides S.N. Mechanisms of immunomodulation by mammalian and viral decoy receptors: Insights from structures. Nat. Rev. Immunol. 2017;17:112. doi: 10.1038/nri.2016.134. - DOI - PubMed
    1. Twumasi-Boateng K., Pettigrew J.L., Kwok Y.E., Bell J.C., Nelson B.H. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer. 2018;18:419–432. doi: 10.1038/s41568-018-0009-4. - DOI - PubMed
    1. Bommareddy P.K., Shettigar M., Kaufman H.L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 2018;18:498. doi: 10.1038/s41577-018-0014-6. - DOI - PubMed
    1. Martin N.T., Bell J.C. Oncolytic virus combination therapy: Killing one bird with two stones. Mol. Ther. 2018;26:1414–1422. doi: 10.1016/j.ymthe.2018.04.001. - DOI - PMC - PubMed
    1. Chon H.J., Lee W.S., Yang H., Kong S.J., Lee N.K., Moon E.S., Choi J., Han E.C., Kim J.H., Ahn J.B., et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin. Cancer Res. 2019;25:1612–1623. doi: 10.1158/1078-0432.CCR-18-1932. - DOI - PubMed